The safety of rosiglitazone in the treatment of Type 2 diabetes
about
Discovery of p1736, a novel antidiabetic compound that improves peripheral insulin sensitivity in mice modelsInsulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione.Diabetes mellitus: new challenges and innovative therapies.Histopathological Evaluation of Heart Toxicity of a Novel Selective PPAR-γ Agonists CKD-501 in db/db MiceRosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.Effectiveness of the early addition of rosiglitazone to control hyperglycemia after unsuccessful submaximal sulphonylurea monotherapy: the Rosiglitazone Early Versus SULphonylurea Titration (RESULT) Study.
P2860
The safety of rosiglitazone in the treatment of Type 2 diabetes
description
im September 2008 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2008
@uk
name
The safety of rosiglitazone in the treatment of Type 2 diabetes
@en
The safety of rosiglitazone in the treatment of Type 2 diabetes
@nl
type
label
The safety of rosiglitazone in the treatment of Type 2 diabetes
@en
The safety of rosiglitazone in the treatment of Type 2 diabetes
@nl
prefLabel
The safety of rosiglitazone in the treatment of Type 2 diabetes
@en
The safety of rosiglitazone in the treatment of Type 2 diabetes
@nl
P2860
P356
P1476
The safety of rosiglitazone in the treatment of Type 2 diabetes
@en
P2093
Yoon K Loke
P2860
P304
P356
10.1517/14740338.7.5.579
P407
P50
P577
2008-09-01T00:00:00Z